01 — Challenge
The challenge
Atrial fibrillation is a common arrhythmia, estimated to affect about 60 million people worldwide. Recurrence after catheter ablation is still discussed as a clinical challenge.
Vision
Toward a future where
cardiac electrophysiology
is understood more deeply.
OpMap Inc. is a University of Tokyo startup researching and developing software for cardiac electrophysiology, including atrial fibrillation ablation.
NoticeOur software is at the research and development stage. It is not approved or cleared for clinical use in any jurisdiction, in Japan or overseas. Nothing on this site is intended as advertising for a medical device.
About
About OpMapVision
Toward a future where cardiac electrophysiology is understood more deeply.
The heart beats in response to electrical signals, and much about how that electrical activity behaves is still not fully understood. We believe that deepening this understanding, step by step, can open up new options for the care of people with arrhythmias.
Mission
Turning clinical questions into research and development, through engineering.
Starting from the questions that arise in arrhythmia care, we bring together expertise in medicine, engineering, and business development to research and develop software for cardiac electrophysiology.
Value 01Start from the clinicOur questions always begin in clinical practice.
Value 02Speak with factsWe share only what we have confirmed, and we share it honestly.
Value 03Cross boundariesWe connect medicine and engineering, and Japan and the world.
Approach
What we work on02 — Approach
Our approach
The heart’s electrical signals may hold more information than conventional measurement reveals. We are exploring that possibility from the software side, through research and development.
03 — Research
Academic background
Our work builds on published research. We presented related research findings at the Heart Rhythm Society annual meeting (HRS 2024).
04 — Status
Where we are now
Our software is at the research and development stage and has not been approved or certified as a medical device in Japan or any other jurisdiction.
Team
The people behind OpMapCo-Founder & Representative Director
Akihiro Komasa
小正 晃裕
Board-certified cardiologist and cardiac electrophysiologist. Completed the Medical MBA Executive Course at Juntendo University (non-degree program).
Director & CSO
Naoki Tomii
富井 直輝
Associate Professor, Research Center for Advanced Science and Technology, The University of Tokyo. PhD in Engineering. After working in industry, he served as Assistant Professor at the Graduate School of Medicine and the Graduate School of Engineering, The University of Tokyo, before taking up his current position in 2024. His research focuses on biomedical engineering, including biosignal processing, medical imaging, and arrhythmia.
Director & CEO
Hiroshi Seno
瀬野 宏
Assistant Professor, Institute of Integrated Research, Institute of Science Tokyo. Previously Assistant Professor at the Graduate School of Engineering, The University of Tokyo. His research focuses on biomedical engineering, including signal processing and machine learning.
Partnership
Who we would like to meet01 — IndustryBusiness development teams at medical device companies and distributors in the arrhythmia / EP field
Partnership →02 — ClinicalElectrophysiologists and centers interested in clinical evaluation
Research collaboration →03 — InvestorsInvestors with an interest in medical software from Japan
Investment →04 — CareersCXO candidates in regulatory affairs, engineering, and business development
Joining the team →Contact
For partnerships, research collaboration, investment, or joining the team, please get in touch.